Company
United StatesPublic company, NYSE: DGXQuest Diagnostics (NYSE: DGX), Lenexa, KS – FDA Inspections
Inspection records and compliance data for Quest Diagnostics in Lenexa, Kansas. 1 FDA inspection on record, last inspected May 23, 2019. Publicly traded as NYSE: DGX.
Company Profile
This profile covers Quest Diagnostics based in Lenexa, Kansas, United States.
FDA Inspection History
- FDA inspections
- 1
- OAI
- 0
- VAI
- 1
- NAI
- 0
- Form 483s
- 0
- Warning letters
- 0
Inspected May 23, 2019.
FDA inspections (1)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| May 23, 2019 | VAI | Human Drugs · Bioresearch Monitoring | 1093466 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Quest Diagnostics
Stock ticker
DGX
Exchange
NYSE
Share price
$254.20
Market cap
$28.0B
Price as of
November 6, 2026
FEI Number
3005821736
Address
10101 Renner Blvd, Lenexa, Kansas 66219, United States
Country
United States
ID: 367bbe98-14b6-4ef8-a4b7-a18355946574